Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

This episode of the Endocrine Outlook features a conversation with Juan Frias, MD, medical director of the National Research Institute. Frias is also the principal investigator of the SURPASS-2 trial which examined Eli Lilly’s Dual GLP1/GIP agonist tirzepatide against 1mg semaglutide for glucose control and weight loss in patients with diabetes.

Episode metadata supplied by the publisher feed · Published Mar 15, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD

0:00 20:46

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 20 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on March 15, 2021.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!